Skip to main content
OpenTrials
Completed

NCT Number: NCT02386852

Ginseng and Ginkgo Biloba Effects on Cognition as Modulated by Cardiovascular Reactivity

There is some evidence to suggest that ginseng and Ginkgo biloba can improve cognitive performance, however, very little is known about the mechanisms associated with such improvement. Here, we tested whether cardiovascular reactivity to a task is associated with cognitive improvement.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Blood Pressure Cognition

Age range

18 year–30 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Department of Psychology, Sunway University

Sunway City, Selangor, 47500, Malaysia

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteers ranging in age between 18 and 30.

Exclusion criteria

  • Ginseng group: exclude those that regularly consume caffeine or Panax Ginseng, or those that are diabetic, have hormone sensitive conditions, autoimmune diseases, bleeding conditions, heart conditions or take medications that are known to interact with Panax Ginseng. These include anticoagulants, Warfarin, Ibuprofen, MAOIs, medications that are changed by the liver, and stimulant drugs (e.g. pseudoephedrine, epinephrine).
  • Ginkgo Biloba group: exclude those that regularly consume caffeine or Ginkgo Biloba, or those that are diabetic, have experienced seizures in the past, have bleeding disorders, or take medications that are known to interact with Ginkgo Biloba. These include Ibuprofen, anticoagulants, Warfarin, Buspirone, Fluoxetine, Trazodone

Treatment and study plan

Placebo

Drug

Study subjects received, in a double blind fashion, placebo pills identical to the drug (drug 1-ginseng, group 1; drug 2-ginkgo biloba-group 2)

Ginseng

Drug

The ginseng group received two capsules containing either 1000 mg or 500 mg of Panax Ginseng extract standardized to 3% of ginsenosides (GNC, USA) or similarly looking placebo capsules over a period of three days of testing.

Ginkgo biloba

Drug

The ginkgo group received two capsules containing either 240 mg or 120 mg of ginkgo biloba extract standardized to 24% ginkgo flavone glycosides and 6% terpene lactones (GBE24/6) or similarly looking placebo capsules over a period of three testing days.

Primary outcomes

  1. Cognitive performance as modulated by either ginseng or ginkgo biloba

    Time frame: Acute effects (3 days of testing)

    Cognitive effects on tests of vigilance/attention, behavioural flexibility and executive functioning

Secondary outcomes

  1. Cardiovascular reactivity as a result of ginseng or ginkgo biloba intake

    Time frame: Acute effects (3 days of testing)

    Changes in systolic, diastolic and heart rate reading as a result of ginseng or ginkgo biloba intake and dependent upon the type of cognitive domain assessed (i.e. vigilance, behavioural flexibility or executive functioning.

Sponsors and collaborators

Lead sponsor

Sunway University

Other

Registry information

Important dates

Study start
2014
Primary completion
2014
Study completion
2014
First posted
Mar 12, 2015
Registry last updated
Mar 13, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.